Search - tctmd.com

Displaying 561 - 580 of 612

Sort: Relevancy | Date

Presentation TCT 2016

Regenerative Products In Perspective: Do They Really Work? Are They Enough?

Presenter: Emerson C. Perin, Ricardo Sanz-Ruiz, Jens Kastrup

October 31, 2016

Presentation TCT 2016

Personalized Medicine Where Are We in 2016?

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Anti-inflammatory Therapies for Atherosclerosis

Presenter: Robert A. Harrington, A. Michael Lincoff, Jean-Claude Tardif

October 30, 2016

Presentation TCT 2016

Heart Failure Advances (Ivabradine, ARNI, and More)

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Presenter: Robert A. Harrington, A. Michael Lincoff, Norman E. Lepor

October 30, 2016

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presenter: David J. Moliterno

October 30, 2016

Presentation TCT 2016

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

Presenter: Paul A. Gurbel, Harvey D. White

October 30, 2016

Presentation TCT 2016

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Sunil V. Rao

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Pharmacotherapy for Hybrid PCI/CABG Cases

Presenter: Sorin J. Brener, Franz-Josef Neumann, Laura Mauri

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Usman Baber

October 30, 2016

Presentation TCT 2016

ACS Case Presentation: Where Pharmacotherapy Failed

Presenter: C. Michael Gibson, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy Clinical Trial Design

Presenter: C. Michael Gibson, Daniel I. Simon, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With STEMI

Presenter: C. Michael Gibson, Daniel I. Simon, Sunil V. Rao

October 30, 2016

Presentation TCT 2016

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With NSTE-ACS

Presenter: C. Michael Gibson, Daniel I. Simon, Glenn N. Levine

October 30, 2016

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Michael O'Riordan

September 13, 2016

Advertisement

Regenerative Products In Perspective: Do They Really Work? Are They Enough?

Personalized Medicine Where Are We in 2016?

Anti-inflammatory Therapies for Atherosclerosis

Heart Failure Advances (Ivabradine, ARNI, and More)

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Pharmacotherapy for Hybrid PCI/CABG Cases

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

ACS Case Presentation: Where Pharmacotherapy Failed

Limitations of Pharmacotherapy Clinical Trial Design

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With STEMI

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With NSTE-ACS

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content